Form D · Other

ABK Biomedical Inc

Halifax, A5 · CIK 0001773773

Offering snapshot reported Nov 3, 2025 · SEC filing

Reported sold
$2.56M
Offering amount: $2.56M
Investors reported
6
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 14, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 3, 2025Initial$2,558,896No comparison6SEC filing
May 13, 2025Initial$26,093,999No comparison24SEC filing
Dec 22, 2022Amendment$28,498,880$10,412,200vs Sep 23, 202223SEC filing
Sep 23, 2022Initial$18,086,680No comparison16SEC filing
Apr 22, 2019Initial$23,499,999No comparison10SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-562869

Source: Form D, filed Nov 3, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Bob Abraham Director, Executive
Aravind Arepally Executive
Lucy Bataneant Executive
Aaron Berez Director
Carissa Bellardine Black Director
David Dobrowski Executive
David Dobrowsky Executive
Gary Donofrio Executive
James Eadie Director
Marc Gregoire Executive
Anthony Headley Executive
Michael Mangano Director, Executive
James Mc Laren Director
Robert Orr Director
Keten Patel Director
Ketan Patel Director
Joseph Siletto Director
Mike Tyson Executive
Michael Tyson Executive

Issuer details

Industry: Other (See others in industry)

Address:
155 Chain Lake Drive, Unit 32
Halifax, A5, B3S 1B3